Rita Colorito

Atezolizumab (Tecentriq) plus bevacizumab (Avastin) resulted in clinically meaningful and durable objective responses as first-line therapy for patients with previously untreated, unresectable disease.

Using dual checkpoint inhibitors in patients with hepatocellular carcinoma is demonstrating activity with a manageable safety profile in both second-line and perioperative settings.

While tomosynthesis has been described by the oncology community as one of the biggest improvements in breast cancer screening, the technology that renders 3D-like images of the breast does carry limitations.

PARP inhibitors still have a place in the treatment paradigm of triple-negative breast cancer, but the role of these agents are significantly evolving.

Despite its substantial progress, much remains unknown about endocrine therapy as a treatment for breast cancer.